Development of a unique platform of specific exosomes: Proof of concept for the solid tumor treatment
For many forms of solid tumors (e.g. brain tumors, osteosarcoma, mammary tumors, melanoma), resection of the tumor and treatment for cancer can lead to damage to the function or appearance of part of the body. body. Solid tumors may also acquire the ability to invade surrounding tissue, join the bloodstream, and then colonize distant tissue to form metastases. Osteosarcoma is a highly malignant solid bone tumor, most commonly occurring in patients aged 10 to 25 years.
Long-term survival is only 60%. Current approaches such as chemotherapy (associated with high resistance) and radiotherapy (having little success in controlling tumor growth) remain associated with extremely invasive surgical resections, up to and including amputation. There is currently no proven clinical evidence supporting alternative therapies (eg CAR-T cells).
There is therefore a definite medical need for access to innovative and improved therapeutic interventions to reduce tumor size before surgery.
There is some evidence to suggest that controlling tumor growth in isolation is not enough to limit damage to surrounding tissue and the risk of metastasis. Indeed, the rapid development of a tumor is due to both (i) the high renewal capacity of tumor cells in (ii) disorganized native tissue, which promotes tissue destruction for tumor development. In this context, the consortium developed the concept of “ONCOGENERATION” (the use of exosomes as a therapeutic intervention in the presence of solid tumors, using an intra-tumor injection to obtain this ONCOGENERATION), based on on a dual mode of action to restore physiological healing of tissues.
The objective of this project is to (i) develop a technological platform to generate specific exosomes to target solid tumors and establish a proof of concept for the use of exosomes as therapy against osteosarcoma, (ii) to obtain, at the end of the project, the ability to perform a first clinical proof of concept in patients with bone tumor.
Consortium Novadip, EVerZom, ULG, CER groupe
Duration: 48 mois
Strategic area : (bio)pharma
Contact: Denis Dufrane, Novadip
